Plaintiff
20 cases as plaintiff.
Watchlist
Email-only, free, anonymous. We'll notify you when Jazz Pharmaceuticals Ireland Ltd. files another patent-infringement lawsuit. One-click unsubscribe from any alert.
Jazz sued Tris Pharma over Tris's January 2026 Section 505(b)(2) NDA for generic Xyrem/Xywav; this docket lists the '426 patent among asserted patents and also lists '400, '181, '494, '446, '306, and '302. The matter appears active.
Jazz Pharmaceuticals Ireland Ltd. sued Granules India Limited; 14 patents were asserted including the '400 patent. The case was terminated by consent judgment dismissing with prejudice on 2026-03-26.
Jazz sued Alkem in a Xyrem-related ANDA action; the complaint asserted the '426 patent plus other patents. The case was voluntarily dismissed, with a Rule 41(a)(1)(A)(i) order signed Oct. 5, 2023, and the case terminated.
Jazz sued Teva over Teva's ANDA for generic Xywav; the complaint lists the '426 patent among the patents-in-suit. Teva filed invalidity contentions and counterclaims; the case was consolidated with the Lupin actions on Dec. 15, 2023, and remains ongoing with no final judgment on '426 found.
Jazz Pharmaceuticals Ireland Ltd. sued Lupin Ltd. in the District of New Jersey. The case was filed 2023-01-20 and terminated 2023-02-16.
Patent infringement action involving Jazz Pharmaceuticals entities and Avadel entities; resolved in the same October 2025 global settlement and stipulation of dismissal with prejudice entered October 27, 2025.
Jazz sued Lupin over Lupin's ANDA No. 215911 for generic Xywav; the complaint expressly lists the '426 patent among ten patents-in-suit. Lupin answered and counterclaimed; the case was consolidated with later Lupin suits and the Teva action, with no final merits judgment on the '426 patent found.
Jazz Pharmaceuticals Ireland Ltd. sued Lupin Inc. in the District of New Jersey. The docket is listed in the patent's Google Patents record and was active with activity into 2026.
Jazz entities sued Mallinckrodt Inc. in D.N.J. involving the '106 patent. The case was closed and later settled.
Jazz Pharmaceuticals Ireland Ltd. sued Ascent Pharmaceuticals in D.N.J. involving the '106 patent. The case was closed.
Jazz Pharmaceuticals and Jazz Pharmaceuticals Ireland sued Wockhardt entities in D.N.J. over ANDA No. 207526. Wockhardt filed counterclaims for declaratory judgment of invalidity/non-infringement of the '988 patent and others, and later settled before the Federal Circuit decision.
Resolved by a stipulation/consent judgment of dismissal. Wockhardt admitted the ANDA filing was a technical act of infringement of the asserted patents, expressly including 8,772,306, and was enjoined except as permitted by the April 18, 2016 license agreement.
The '306 patent was asserted; Roxane moved to dismiss the '306 claims on §101 subject-matter eligibility, which the court administratively terminated and stayed discovery on pending IPR. The case was consolidated with Roxane's '302 case on Mar 24, 2016 and settled in April 2017.
DrugPatentWatch lists 8,324,275 as asserted in Jazz Pharmaceuticals v. Roxane Laboratories; the case was resolved via the April 2017 Jazz–Roxane settlement.
Consolidated D.N.J. Xyrem action in which the '306 patent was folded in and construed in the court's Markman decision. Terminated by Amneal settlement on Oct 15, 2018.
The '306 patent was asserted against Lupin. The case settled on June 12, 2018, as described in antitrust complaints.
D.N.J. Xyrem ANDA action against Watson, consolidated with the Ranbaxy and Amneal Xyrem actions for a 500 mg/ml generic sodium oxybate oral solution. The narrative identifies it among the Hatch-Waxman suits filed by Jazz on US 6,780,889; it was resolved/terminated in the 2015-2018 window.
A District of New Jersey docket listed in the patent's family-level litigation data. Party details were not confirmed in the narrative.
Jazz Pharmaceuticals Ireland Ltd. sued Tris Pharma, Inc. in the District of New Jersey. Judge Stanley R. Chesler denied Tris's motion to dismiss on July 8, 2026, and an answer, counterclaim, and scheduling order followed.
The '275 patent appears in the list of patents-in-suit recited in the consolidated D.N.J. Watson pleadings; resolved by settlement. Consolidated with 14-6151 and 15-187.